Skip to main content

Table 1 Pancreatic adenocarcinoma Incidence rates (1973-2014)

From: Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study

Characteristic

Incidence of pancreatic adenocarcinoma

Incidence of adenocarcinoma of the head of pancreas

Incidence of adenocarcinoma of the body and tail of pancreas

Cases, No (%)a

Rate (95% CI)b

Cases, No (%)a

Rate (95% CI)b

Cases, No (%)a

Rate (95% CI)b

Overall

67,878 (100)

6.95 (6.90 - 7.00)

33,728 (100)

3.46 (3.42 - 3.50)

14,321 (100)

1.46 (1.43 - 1.48)

Sex

 Male

35,062 (51.65)

8.16 (8.07 - 8.24)

17,033 (50.50)

3.98 (3.92 - 4.04)

7,666 (53.53)

1.76 (1.72 - 1.81)

 Female

32,816 (48.35)

5.99 (5.93 - 6.06)

16,695 (49.50)

3.05 (3.00 - 3.09)

6,655 (46.47)

1.22 (1.19 - 1.25)

Race

 White

55,222 (81.35)

6.77 (6.71 - 6.83)

27,492 (81.51)

3.37 (3.33 - 3.42)

11,414 (79.70)

1.40 (1.37 - 1.42)

 Black

7,797 (11.49)

9.85 (9.63 -10.08)

3,961 (11.74)

5.02 (4.86 - 5.19)

1,727 (12.06)

2.16 (2.05 - 2.27)

 Othersc

4,755 (7.01)

5.80 (5.63 - 5.97)

2,229 (6.61)

2.72 (2.61 - 2.84)

1,153 (8.05)

1.39 (1.31 - 1.48)

 Unknownd

104 (0.15)

-

46 (0.14)

-

27 (0.19)

-

Age at diagnosis, y

 <60

16,305 (24.02)

1.93 (1.90 - 1.96)

7,729 (22.92)

0.92 (0.90- 0.94)

3,750 (26.19)

0.44 (0.43 - 0.46)

 >60

51,573 (75.98)

32.28 (32.00 - 32.56)

25,999 (77.08)

16.30 (16.10 - 16.50)

10,571 (73.81)

6.58 (6.46 - 6.71)

Statee

 California

10,960 (16.15)

7.06 (6.93 - 7.20)

5,563 (16.49)

3.60 (3.50 - 3.69)

2,347 (16.39)

1.50 (1.44-1.56)

 Connecticut

10,906 (16.07)

7.41 (7.27 - 7.55)

5,363 (15.90)

3.64 (3.54 - 3.74)

2,306 (16.10)

1.57 (1.51-1.63)

 Georgia

5,113 (7.53)

7.09 (6.89 - 7.29)

2,585 (7.66)

3.61 (3.46 - 3.75)

1,178 (8.22)

1.61 (1.52-1.71)

 Hawaii

2,955 (4.35)

6.47 (6.23 - 6.71)

1,316 (3.90)

2.88 (2.73 - 3.04)

700 (4.89)

1.53 (1.41-1.64)

 Iowa

9,079 (13.38)

6.75 (6.61 - 6.89)

4,631 (13.73)

3.42 (3.33 - 3.53)

1,941 (13.55)

1.46 (1.39-1.52)

 Michigan

12,539 (18.47)

7.87 (7.73 - 8.01)

6,182 (18.33)

3.89 (3.79 - 3.99)

2,556 (17.85)

1.60 (1.53-1.66)

 New Mexico

3,890 (5.73)

6.09 (5.89 - 6.28)

1,928 (5.72)

3.01 (2.87 - 3.15)

671 (4.69)

1.04 (0.96-1.12)

 Utah

3,172 (04.67)

5.32 (5.13 - 5.51)

1,581 (4.69)

2.67 (2.54 - 2.81)

667 (4.66)

1.11 (1.02-1.19)

 Washington

9,264 (13.65)

6.68 (6.55 - 6.82)

4,579 (13.58)

3.31 (3.22 - 3.41)

1,955 (13.65)

1.40 (1.34-1.47)

Stage at diagnosisf

 Localized

5,796 (8.54)

0.60 (0.58 - 0.62)

3,678 (10.90)

0.38 (0.37 - 0.40)

1,123 (7.84)

0.11 (0.11 - 0.12)

 Regional

18,623 (27.43)

1.90 (1.88 - 1.93)

13,193 (39.12)

1.35 (1.33 - 1.37)

2,140 (14.94)

0.22 (0.21 - 0.23)

 Distant

38,852 (57.24)

3.96 (3.92 - 3.998)

14,685 (43.54)

1.50 (1.47 - 1.52)

10,600 (74.02)

1.08 (1.06 - 1.10)

 Unstaged

4,607 (6.79)

0.48 (0.47-0.50)

2,172 (6.44)

0.23 (0.22-0.24)

458 (3.20)

0.05 (0.04-0.05)

  1. aCases included first primary tumors that matched the selection criteria, were microscopically confirmed, and were not identified only from autopsy records
  2. or death certificates
  3. bRates were calculated as number of cases per 100,000 person-years and age adjusted to the 2000 US standard population
  4. cIncludes American Indian/Alaskan Native and Asian/Pacific Islander
  5. dRates for patients with unknown race could not be calculated, as ‘race’ is a population variable and must be known to calculate rates
  6. eRates were calculated between 1973-2014 for all states except Georgia; 1975-2014, and Washington; 1974-2014
  7. fUsing SEER historic stage A
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us